News & Events

Simtra is driving the future of sterile injectable manufacturing with cutting-edge investments in ADCs, expanded fill-finish capacity, and enhanced development services. As the demand for complex therapies grows, our commitment to quality, efficiency, and patient-centered innovation has never been stronger.

DCAT Week 2025, Lidia Serina, Ph.D., Head of Development Services at Simtra BioPharma Solutions, shares insights into the challenges of maintaining aseptic integrity and stability in sterile injectable manufacturing with BioPharm International.

Simtra BioPharma Solutions expands capabilities with $14M investment for accelerated development and manufacturing of antibody-drug conjugates (ADCs) as part of the scaling of its development services business.

Simtra BioPharma Solutions, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectables, is pleased to announce the appointment of Dr. Mike Schäfers, Ph.D., as Chief Commercial Officer and Head of Business Development.

Simtra BioPharma Solutions, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectables, is pleased to announce the appointment of Dr. Lidia Serina, Ph.D., as Head of Development Services.

Simtra BioPharma Solutions (Simtra), a premier injectable contract development and manufacturing organization (CDMO), today announced a $250+ million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana.

Simtra BioPharma Solutions (Simtra), a leading sterile injectable contract development and manufacturing organization (CDMO), proudly announces the establishment of its new corporate headquarters at 400 Interpace Parkway, Building C, Suite 270, Parsippany, New Jersey.

Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced that it has signed a definitive agreement to divest its BioPharma Solutions (“BPS”) business to Advent International (“Advent”), one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor.

Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced an approximately $100 million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany.